Opinion

Video

Patient Case 2: Metastatic CSPC

Author(s):

Stephen J. Freedland, MD,Eleni Efstathiou, MD, PhD

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.

Video content above is prompted by the following questions:

  • What is your initial impression of this patient and their risk stratification?
    • What biomarker testing and imaging would you recommend?
    • How would you assess the burden and distribution of metastatic disease?
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Bertram Yuh, MD, MISM, MSHCPM
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Oliver Sartor, MD
October 23rd 2024

177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center
June 20th 2024

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

Fred Saad, MD, FRCS
October 17th 2024

ARANOTE Data Highlight Darolutamide Plus ADT as a Potential Chemo-Free Option in mHSPC

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Darolutamide Plus ADT in mHSPC: © vitanovski - stock.adobe.com
October 14th 2024

EU Approval Sought for Darolutamide Plus ADT for mHSPC

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.
October 12th 2024

The OncFive: Top Oncology Articles for the Week of 10/6